NCT01816672终止不适用
A Multi-Center, Prospective, Clinical Trial Comparing the Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner 1 and 2 Diabetic Foot Ulcers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Cytomedix
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Compare time to heal in Wagner 1 and 2 diabetic foot ulcers at 12 weeks treated with AutoloGel versus usual and customary care
研究概览
简要总结
The purpose of this study is to determine if AutoloGel platelet rich plasma used on non healing diabetic foot ulcers Wagner gd. 1 and 2 is more effective then the usual and customary care
详细描述
Autologel is a platelet-rich plasma gel used in the treatment of no-healing chronic wounds. Prospective observational studies of the effectiveness of Autologel have demonstrated promising results in regard to the healing of diabetic foot ulcers including severe Wagner grade 3 and 4 ulcers. The aim of the current trial is to compare the efficacy, measured as wound healing in a single-blind (assessor) randomized controlled trial, of usual and customary care with and without Autologel in treating Wagner 1 and 2 diabetic foot ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Medicare eligible
- •≥18 years of age
- •Type I or II diabetes requiring medical treatment as determined by the physician
- •The largest non-healing wound, if multiple wounds are present, or the single wound to be treated (index ulcer) is a Wagner 1 or 2 Diabetic Foot Ulcer (DFU; see Appendix 9 for Wagner Classification) that is located on the plantar, medial, or lateral aspect of the foot (including all toe surfaces but not on the heel). Subjects who have heel ulcers may be included if another, eligible wound is the index ulcer
- •For subjects with potentially multiple eligible DFUs, the largest ulcer will be selected. There must be at least 4 cm between the index ulcer and other ulcers; if all ulcers are closer than 4 cm, the subject should not be enrolled (screen failure)
- •Debrided ulcer size between 0.5 cm2 and 20 cm2
- •Demonstrated adequate offloading regimen
- •Duration ≥ 1 month at first visit (screening period)
- •Subject must be willing to comply with the Protocol, which will be assessed by enrolling clinician.
排除标准
- •Subjects known to be sensitive to AutoloGel components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin
- •Wagner 3, 4, or 5 DFU (see Appendix 9 for Wagner Classification) Page 15 of 58
- •Any clinically infected index ulcer that is apparent on Day
- •The presence of infection is defined by ≥ 2 classic findings of inflammation (erythema, warmth, tenderness, pain, or induration) or purulent secretions (Lipsky, 2012, or see Appendix 4)
- •Presence of another wound that is concurrently treated and might interfere with index wound
- •Ulcer not of DFU pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, pressure, or arterial etiology)
- •Presence of underlying osteomyelitis, or if osteomyelitis is suspected
- •Received systemic corticosteroids or immunosuppressive agents, hyperbaric oxygen therapy (HBOT), electrostimulation, growth factors, or any cell or tissue-derived products for wounds during the 30 days preceding the screening visit; received radiation therapy or chemotherapy within previous 6 months
- •Any malignancy other than non-melanoma skin cancer
- •Ischemic ulcer defined as an ankle brachial index (ABI; handheld or Arterial Doppler) < 0.8 (note: if ABI is ≥ 1, then an skin perfusion pressure (SPP) or transcutaneous oximetry (TCOM) must be performed or the subject cannot be enrolled), TCOM < 30 mm Hg, or SPP < 30 mm Hg; toe pressure < 45 mm Hg. These measurements may be concurrent with the initial evaluation of the index ulcer or obtained within 90 days of study enrollment if done prior to that concurrence.
- •Subject has radiographic evidence consistent with diagnosis of active Charcot foot
- •Untreated Charcot foot or DFUs associated with a treated Charcot deformity in which reconstruction or offloading has not taken place
- •Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)
- •Ulcer area decreases by ≥ 30% during 2-week screening/run-in period
- •Subjects who are cognitively impaired and do not have a healthcare proxy
- •Serum albumin of less than 2.5 g/dL
- •Plasma Platelet count of less than 100 x 109/L
- •Hemoglobin of less than 10.5 g/dL
- •Subject has inadequate venous access for repeated blood draw required for AutoloGel Administration
- •Subject requires or is anticipated to require interventions directed at improvement of arterial perfusion to affected area.
结局指标
主要结局
Compare time to heal in Wagner 1 and 2 diabetic foot ulcers at 12 weeks treated with AutoloGel versus usual and customary care
时间窗: 12 weeks
Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements confirmed at consecutive study visits 2 weeks apart. Initial diagnosis of healing by unblinding Principal Investigator will be confirmed by an independent blinded observer using digital photography, planimetry data and wound measurements
次要结局
- Assess wound healing trajectory and change in Chronic Wound quality of Life W-QOL scores: and to assess the comparative safety of AutoloGel and usual and customary care(13 weeks)
- Number of patients with adverse events as a measure of tolerability(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
2 期
The Effect of Platelet-rich Plasma in Subjects With Androgenetic AlopeciaAndrogenetic AlopeciaNCT03048461Northwestern University
已完成
不适用
Autologous Platelet Rich Plasma Combined to Hyaluronic Acid Obtained With Regen-Kit BCT-HA in Aesthetic MedicineSkin WrinklingNCT02832583Regen Lab SA31
Unknown
2 期
Use of Autologous Plasma Rich in Platelets and Extracellular Vesicles in the Surgical Treatment of Chronic Middle Ear InfectionsOtitis Media ChronicTympanic Membrane PerforationNCT04761562University Medical Centre Ljubljana100
进行中（未招募）
2 期
Platelet-rich Plasma for EyebrowsEyebrow HypotrichosisNCT04018859Northwestern University11
Unknown
不适用
Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic AlopeciaHair LossAlopeciaAndrogenetic AlopeciaNCT02393040Universitat Internacional de Catalunya50